ots Ad hoc-Service: Girindus AG <DE0005880405> Girindus receives DEM 9.4 million subsidy to develop innovative biotechnology processes
Bensberg (ots Ad hoc-Service) -
Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement.
- Girindus receives DEM 9.4 million subsidy to develop innovative biotechnology processes - The commerce department of the state of North Rhine- Westphalia (NRW) supports the biotech company in Bensberg under its technology program
Girindus anticipates to spend approximately DEM 24 million on biotechnological processes for the production of API's (Active Pharmaceutical Ingredients) by the year 2002. The State of North Rhine-Westphalia has notified the company that relevant projects will be supported by subsidy funds totalling DEM 9.4 million.
Girindus will use the funds to make investments targeting at key technologies strengthening the company's market position. Girindus is positioned as a one-stop-shop for biotechnology and pharmaceutical companies and is active in the key areas of process development, scale-up and the manufacturing of active pharmaceutical ingredients in accordance with cGMP and regulatory support.
Activities that are subsidized include projects to improve the production of active pharmaceutical ingredients through the combination of microbiological, enzymatic and chemical processes. In addition, processes for the genetic modification of microorganisms are developed to improve the production of biotechnologically produced active pharmaceutical ingredients.
After successful completion of R&D, the projects will be scaled up to expand the biotechnological process portfolio of Girindus.
The process R&D is especially done in a close cooperation with universities and research institutes located in North Rhine- Westphalia.
Girindus (Neuer Markt, Frankfurt/Germany: GIR, Share ID Number 588040) has the comprehensive know-how and the technologies essential to optimize processes for the production of drugs. With key competencies in process development, scale-up and cGMP- (current Good Manufacturing Practice) compliant production with regulatory support, Girindus offers its partners a one-stop- shop solution for all clinical trial phases between drug discovery and market entry. The high standard of quality was recently reconfirmed by a renewed inspection by the U.S. health authority FDA.
Results for the third quarter of the current fiscal year correspond with expectations and will be made available with publication of the quarterly report available as of December 1, 2000. Further information is available at www.Girindus.com.
Contact:
Girindus AG
Barbara Scharte, Investor Relations Manager
bscharte@girindus.com
Telephone: ++49 2204 926 934
End
Internet: http://recherche.newsaktuell.de
Original-Content von: Girindus AG i.L., übermittelt durch news aktuell